Marker Therapeutics (NASDAQ:MRKR) Announces Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Marker Therapeutics (NASDAQ:MRKR) released its earnings results on Monday. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14), Zacks reports. The company had revenue of $1.22 million for the quarter, compared to analysts’ expectations of $5.25 million. Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%.

Marker Therapeutics Stock Performance

Shares of NASDAQ MRKR traded down $0.09 during mid-day trading on Tuesday, reaching $1.14. The company’s stock had a trading volume of 119,212 shares, compared to its average volume of 58,826. Marker Therapeutics has a 52 week low of $1.10 and a 52 week high of $5.99. The stock has a fifty day moving average of $1.60 and a two-hundred day moving average of $2.72.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on MRKR shares. WBB Securities reaffirmed a “strong-buy” rating and set a $12.50 price objective on shares of Marker Therapeutics in a research report on Tuesday. Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th. Finally, Canaccord Genuity Group began coverage on shares of Marker Therapeutics in a research report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price target for the company.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.